CP
CRSP icon

Corbenic Partners’s CRISPR Therapeutics CRSP Stock Holding History

Corbenic Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1K Sell
20
-40
-67% -$2.35K ﹤0.01% 196
2022
Q1 		$4K Sell
60
-660
-92% -$41.4K ﹤0.01% 185
2021
Q4 		$55K Sell
720
-45
-6% -$3.93K 0.01% 81
2021
Q3 		$86K Hold
765
– – 0.02% 73
2021
Q2 		$124K Hold
765
– – 0.03% 60
2021
Q1 		$93K Buy
+765
New +$116K 0.02% 69

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Corbenic Partners's CRSP Position: Q2 2022 in Review

Corbenic Partners reduced its CRISPR Therapeutics (CRSP) stake by 67% in Q2 2022, selling an estimated $2.35K and leaving 20 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #196.

Corbenic Partners first reported a position in CRSP in Q1 2021 and has held it in 6 quarters since. The position peaked at $124K in Q2 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • Corbenic Partners held 20 shares of CRISPR Therapeutics worth $1K as of Q2 2022.
  • Corbenic Partners sold 40 CRISPR Therapeutics shares in Q2 2022, an estimated $2.35K.
  • CRISPR Therapeutics made up ﹤0.01% of Corbenic Partners's portfolio in Q2 2022, its #196 holding.
  • Corbenic Partners first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Corbenic Partners's CRISPR Therapeutics position peaked at $124K in Q2 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Corbenic Partners's 13F filing for Q2 2022, filed 25 Jul 2022.